Gout is translated from Greek as “like a foot-trap”, and this disease is also known as the “disease of the aristocrats”. Gout has been known to mankind since ancient times; the first written mention of gout was found in ancient Egypt, then this topic was raised more than once in the works of such pillars of medicine as Hippocrates, Celsus, and Galen. This problem remains relevant in the modern world as well. Most often, men over 40 years of age suffer from this disease, but there is currently an increase in the incidence of gout, including in women and young people. So, what is gout? Gout is a chronic polyetiological disease associated with a purine metabolism disorder, characterize by an increase in the level of uric acid in the blood (hyperuricemia) and the deposition of the sodium salt of uric acid (urate) in the joints, periarticular tissues and internal organs with the development of recurrent arthritis and the formation of gouty nodules (tophi). The aim of our research was to study the features of gout pharmacotherapy. To achieve it, the following tasks were set and fulfilled: the mechanism of development of gout as a hereditary polyetiological disease was considered, and the biochemical aspects of the formation and course of the disease were highlighted. Treatment is prescribed depending on the period of the disease, including drugs for stopping an attack (NSAIDs, colchicine, corticosteroids and monoclonal antibodies) and maintenance therapy in the interictal period (allopurinol and uricosuric drugs). In the course of the work, we were interested in the mechanisms of action of drugs such as allopurinol and colchicine, therefore, these were given special attention.
Read full abstract